Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Role of Echocardiography and Ultrasound Indices in Resuscitation of Septic Shock Patients

NCT07550400 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-05-03
Last updated
2026-04-24

Condition(s) studied

Septic ShockFluid Resuscitation

Investigational drug(s) / intervention(s)

carotid artery duplexLeft ventricular end diastolic area

carotid artery duplex: , Carotid Doppler (T0) will be performed within 1-2 Hours of ICU Admission to measure the following parameters: "Peak systolic velocity" and Velocity Time Integral over the common carotid artery. Using the linear probe (VF12-4) of ultrasound machine (ACUSON NX3, Siemens Medical solution USA, Inc.) * According to surviving sepsis campaign guidelines 2021, patients diagnosed with septic shock should be given 30ml/kg IV crystalloid fluid within the first 3 hours, the fluid will be given in the form of 500 ml boluses, each bolus should be given in 15 minutes. * FC "fluid challenge" will be performed by rapid volume infusion over (30minutes) of 1000mL Ringer acetate solution. * Carotid artery Duplex parameters will be repeated. Relative changes in "Peak Systolic Velocity, Velocity Time integral" will be expressed in

Left ventricular end diastolic area: * Echocardiography (T0) will be performed within 1-2 Hours of ICU Admission to measure LVEDA if less than 10 cm2 then the patient will be considered hypovolemic. * According to surviving sepsis campaign guidelines 2021, patients diagnosed with septic shock should be given 30ml/kg IV crystalloid fluid within the first 3 hours, the fluid will be given in the form of 500 ml boluses, each bolus should be given in 15 minutes. * FC "fluid challenge" will be performed by rapid volume infusion over (30minutes) of 1000mL Ringer acetate solution. * After five minutes from FC "fluid challenge" (T1), echocardiography will be repeated to re-measure LVEDA. Pt will be defined as a responder if LVEDA b

Study summary

Fluid replacement is considered the cornerstone of hemodynamic management in critically ill patients especially in patients with septic shock. However, only about 50% of critically ill hemodynamically unstable patients are responsive to fluids. Consequently, the resuscitation of critically ill patients requires an accurate assessment of the patients' intravascular volume status and their volume responsiveness. In this study, we will compare the efficacy of carotid artery flow to echo left ventricular end diastolic volume as a predictive value for fluid resuscitation in septic shock patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * ▪ Age:18-50 years old * Sex: both males \&females. * Patients diagnosed with septic shock according to SOFA score more than or equal 1 * Presence of at least one sign of acute circulatory failure from: 1. Low blood pressure (mean arterial pressure \<65 mmHg and / or systolic \<90 mmHg). 2. Tachycardia\> 120 bpm without other obvious cause of circulatory failure. 3. Oliguria \<1 ml / kg during the last hour suggestive of circulatory failure. 4. Blood hyperlactatemia \> 2mmol / l without other obvious cause a systemic circulatory failure. 5. Another sign justifying, for example vascular increase capillary refill time more than 2 seconds. Exclusion Criteria: * ▪ Known significant valvular heart disease (sever aortic insufficiency or stenosis) * Known carotid artery stenosis \>50% or previous carotid surgery * Clear contraindication to the carotid artery Doppler such as wound or infection or complete or partial occlusion of the carotid artery. * Arrhythmias affect stroke volume assessment (atrial fibrillation, frequent PVCs) * Dilated cardiomyopathy. * Poor transthoracic echocardiographic window * Patient refusal

Primary outcome measure(s)

  • Accuracy of echo and ultrasound indices — 1 Day
    Diagnostic accuracy (sensitivity, specificity) of LVEDA and carotid artery flow parameters (PEAK Systolic Velocity, Velocity time integral (VTI), in predicting fluid responsiveness defined as an increase in stroke volume after a standardized fluid challenge.

Trial sites (1)

FacilityCityRegionStatus
Faculty of medicine, Ain Shams University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07550400 on ClinicalTrials.gov ↗ ← All trials in Egypt